FDA Names APB-102, Potential Gene Therapy for Familial ALS, an Orphan Drug

Defining The Relationship: We’re More than Our Roles

When I was brainstorming ideas for the name of this column, before settling on “Joyful Sorrow,” I asked my husband if he had any ideas. “How about ‘The Caregiver’?” Todd suggested. I dismissed it out of hand. He pushed back. “I think it’s a good name. It’s descriptive and it’s…

Gut Microbiome May Help Slow ALS Progression, Study Indicates

The gut microbiome — the natural collection of microorganisms living in our guts —  might influence the progression of amyotrophic lateral sclerosis (ALS), recent research suggests. Specifically, researchers found that a metabolite produced by the Akkermansia muciniphila bacteria, called nicotinamide, slowed disease progression and prolonged survival in an ALS mouse…

A Few of My Favorite Words to Live By

I always have had a fascination with words. It stems from my mom and dad, both of whom instilled in me a voracious appetite for reading and writing. Letters from my grandfather blending humor, pathos, self-deprecation, irreverence, sobriety, fact, and thoughtful opinion cemented the notion that words, carefully pieced together,…

How I Learned to Love My Rollator

In 2010, a few short months after my ALS diagnosis, I found myself having to rely full time on a rollator. I’ll be the first to admit I wasn’t happy at all. But now, nine years later, it’s become my ever-present silent buddy, and I can’t imagine my life…

Enrollment Complete for ORARIALS-01 Trial of Arimoclomol in ALS Patients

Patient enrollment is now complete, ahead of schedule, for the Phase 3 ORARIALS-01 clinical trial assessing the effectiveness of Orphazyme’s investigational therapy arimoclomol in the treatment of amyotrophic lateral sclerosis (ALS). “The completion of enrollment for Orphazyme’s pivotal ALS trial is another great milestone for our clinical development program. We are confident that…